Five Prime Therapeutics achieved a development milestone for cabiralizumab under the license and collaboration agreement with Bristol-Myers Squibb, triggering a $25 million payment. The milestone was triggered by initiation of a Phase II trial sponsored by BMS, evaluating cabiralizumab and Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. The Phase II trial is expected to enroll approximately 160 patients with locally advanced or metastatic pancrea...